Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.

Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.

Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.

Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.

Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.

Sixteen hard-won lessons on the decisions, blind spots, and timing mistakes that determine whether a healthcare company builds something that holds its value — or leaves money on the table when it matters most.

Revenue growth can mask structural fragility — when performance isn’t systematized, buyers discount valuation because they can’t underwrite what won’t scale or transfer.

In this article, we define narrative debt, explain why late-stage story work can only limit the damage, and lay out what healthcare CEOs should be doing now to resolve it before it affects their valuation.

Build the kind of brand investors believe in. Let’s start aligning your market position with your enterprise value.

At Legacy DNA, we integrate artificial intelligence as an acceleration tool, not a replacement for expertise.

Inside the journey from personal conviction to market dominance and what every healthtech CEO can learn about Exit Readiness.

Founder-led healthcare companies often win early because of the founder’s credibility, relationships, and clinical expertise. But when buyers evaluate the business for an acquisition, they are testing whether the growth engine works without the founder in the room. When that answer is unclear, risk appears.

Here are three traits that instantly separate healthtech legends from the rest and command premium multiples.

High burn isn’t momentum; it’s fragility. See how efficient growth drives higher multiples.

Does fast growth always increase your valuation? Learn how buyers assess growth, red flags that reduce multiples, and how to strengthen exit readiness.